Article
The PI3k inhibitors: new hopes in the battle against advanced NSCLC.
Frontiers in bioscience (Landmark edition) - 1 Jan 2014
Sacco Paola Claudia, Maione Paolo, Rossi Antonio, Barecshino Maria Anna, Sgambato Assunta, Casaluce Francesca, Napolitano Alba, Palazzolo Giovanni, Rossi Emanuela, Ferrara Carmine, Gridelli Cesare
Abstract excerpt
In terms of both incidence and mortality, lung tumor is the most common cancer in the world today. Among lung tumors, 80% are classified as non-small-cell lung cancer (NSCLC) and are mostly diagnosed at an advanced stage (either locally advanced or metastatic disease). Platinum-based doublet chemotherapy, the standard treatment for advanced NSCLC, has reached a plateau of effectiveness and achieves mostly partial...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.